Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772087 | 0.82 | NOTUM (0.47) | NOTUMALDH1A1MEN1KMT2A | |
| SCHEMBL23772062 | 0.78 | CREBBP (0.36) | L3MBTL1CFTR | |
| SCHEMBL23772003 | 0.76 | L3MBTL1 (0.36) | L3MBTL1MEN1KMT2APARP1 | |
| SCHEMBL23772016 | 0.73 | MYC (0.39) | CFTR | |
| SCHEMBL7705143 | 0.71 | ALDH1A1 (0.43) | L3MBTL1NOTUMALDH1A1ATMMEN1 | |
| SCHEMBL891294 | 0.68 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL28912459 | 0.66 | — | — | |
| SCHEMBL1002129 | 0.65 | ALDH1A1 (0.50) | L3MBTL1ALDH1A1MAPTKMT2A | |
| SCHEMBL29577047 | 0.65 | BTK (0.41) | ALDH1A1PARP1 | |
| Hydrochloric Acid SCHEMBL20576674 | 0.64 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251991-A1 | SUBSTITUTED 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HMBS | L3MBTL1 1044/4885NOTUM 2495/4885CFTR 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.